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Background
Chronic graft-versus-host disease (cGVHD) is a major complication after allogeneic stem cell trans-
plantation with an adverse effect on both mortality and morbidity. In 2005, the National Institute
of Health proposed new criteria for diagnosis and classification of chronic graft-versus-host disease
for clinical trials. New sub-categories were recognized such as late onset acute graft-versus-host
disease and overlap syndrome.
Design and Methods
We evaluated the prognostic impact of the new sub-categories as well as the clinical scoring sys-
tem proposed by the National Institute of Health in a retrospective, multicenter study of 820
patients undergoing allogeneic stem cell transplantation between 2000 and 2006 at 3 different
institutions. Patients were retrospectively categorized according to the National Institute of
Health criteria from patients’ medical histories. 
Results
As far as the new sub-categories are concerned, in univariate analysis diagnosis of overlap syn-
drome adversely affected the outcome. Also, the number of organs involved for a cut-off value of
4 significantly influenced both cGVHD related mortality and survival. In multivariate analysis, in
addition to NIH score, platelet count and performance score at the time of cGVHD diagnosis, plus
gut involvement, significantly influenced outcome. These 3 variables allowed us to develop a sim-
ple score system which identifies 4 subgroups of patients with 84%, 64%, 43% and 0% overall
survival at five years after cGVHD diagnosis  (score 0: HR=15.96 (95% CI: 6.85-37.17), P<0.001;
score 1: HR=5.47 (95% CI: 2.6-11.5), P<0.001; score 2: HR=2.8 (95% CI: 1.32-5.93), P=0.007). 
Conclusions
In summary, we have identified a powerful and simple tool to discriminate different subgroups
of patients in terms of chronic graft-versus-host disease related mortality and survival.
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Introduction
Chronic graft-versus-host disease (cGVHD) is a major
complication following allogeneic hematopoietic stem cell
transplantation (HSCT) which impairs patients’ quality of
life and hampers long-term survival.1 Historically, cGVHD
has been classified as ‘limited’ or ‘extensive’ on the basis
of the results from a small retrospective study.2 This sys-
tem was developed primarily to distinguish between
patients requiring systemic immune suppression from
those for whom local care might suffice. Nevertheless, a
majority of patients experience extensive stage cGVHD3
that constitutes an extremely heterogeneous population.
In addition, diagnosis of cGVHD was classically based on
the presence of any manifestation of GVHD beyond 100
days after allogeneic transplantation. Based on expert
opinion, in 2005 the National Institute of Health (NIH)
proposed new criteria for the diagnosis and classification
of cGVHD based on the clinical manifestations and not on
the time of onset.4 According to this proposal, new sub-
categories were recognized both for acute (classic aGVHD
and late-onset aGVHD) and for cGVHD (classic chronic
and overlap syndrome). As far as the prognostic value of
these categories is concerned, few reported studies have
analyzed the impact of delayed aGVHD on outcome,5 and
no study has evaluated the outcome of patients with over-
lap syndrome in a large series of patients. 
Also, the NIH proposed a new clinical scoring system
for the global assessment of cGVHD severity based on the
number of organs involved (with an arbitrary cut-off value
of involvement of more or less than 3 organs to distinguish
between mild versusmoderate) and the degree of function-
al impairment in the affected organs (mild, moderate or
severe) which should allow patients requiring a purely
topical approach versus systemic immune suppression to
be identified, as well as facilitating decisions regarding the
timing and intensity of therapy. Nevertheless, few studies
have been performed to validate this scoring system in a
large series of patients.3,6 Furthermore, this scoring system
is quite time-consuming which makes it difficult to satisfy
all the requirements during a routine out-patient consulta-
tion.4
In this current study, we evaluated the prognostic
impact of the new sub-categories as well as the clinical
scoring system proposed by the NIH Consensus
Development Project. We also tried to identify the most
important variables predicting outcome in a series of 747
patients undergoing allogeneic stem cell transplantation in
3 different institutions in order to build up a simplified
scoring system.
Design and Methods
Patients’ characteristics
Eight hundred and twenty patients undergoing allogeneic stem
cell transplantation in 3 different institutions from January 2000 to
December 2006 were included in the analysis. The analysis was
restricted to those 747 patients surviving more than 100 days after
transplantation. The study protocol was approved by the ethics
committee at Karolinska Institutet and was performed in accor-
dance with the declaration of Helsinki. Written informed consent
was obtained from all patients in Salamanca and Sant Pau. Patients
were retrospectively categorized according to the NIH scoring sys-
tem based on the data collected from patients’ medical histories.
The specified organ involvement and grading was also categorized
according to the classical limited versus extensive classification.
Characteristics of the patients who developed cGVHD are sum-
marized in Table 1. 
Median age at the time of transplantation was 50 years. Median
follow up was 41 months. The most common diagnosis was acute
myeloid leukemia in 24% of patients, acute lymphoblastic
leukemia in 11% and myelodysplastic syndrome in 11%. Twenty-
seven percent of patients were in 1st or subsequent complete
remission at the time of transplant. Eighty-four percent received
hematopoietic stem cells from a related donor and 71% received
reduced intensity conditioning regimens. Sixty percent of the
patients received cyclosporine plus methotrexate and 27%
received in vivo T-cell depletion. 
The first-line treatment of extensive cGVHD was based on CsA
or tacrolimus plus prednisone at 1 mg/kg/day that was switched
to alternate days after four weeks of treatment. The disease
response was generally evaluated five weeks after the introduction
of steroid and then every three months until the end of treatment.
All patients received antibacterial, antifungal and antiviral pro-
phylaxis according to standard procedures.
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Table 1. Patients’ characteristics.
Characteristics of the patients                                     N=336
                                                                                      N (%)
Age
Median (range)                                                                   50 (1-69)
Diagnosis (%)
Acute myeloid leukemia                                                      81 (24)
Acute lymphoblastic leukemia                                           37 (11)
Chronic myeloid leukemia                                                   30 (9)
Myelodysplastic syndromes                                               37 (11)
Multiple myeloma                                                                 31 (9)
Non-Hodgkin's lymphoma                                                  37 (11)
Chronic lymphocytic leukemia                                           20 (6)
Others                                                                                     63 (19)
Disease status at transplant (%)
1st CR                                                                                        91 (27)
2nd or subsequent CR                                                           64 (19)
PR                                                                                             60 (18)
Progressive / relapsed disease                                         71 (21)
Others                                                                                     50 (15)
Sex (%)
Male / female                                                                  (63%) / (37%)
Sex mismatched                                                                  148 (44)
HLA matched (%)                                                                    302 (90)
Source of progenitor cells (%)
Peripheral blood                                                                  279 (83)
Bone marrow                                                                         54 (16)
Cord blood                                                                               3 (1)
Type of donor (%)
Related                                                                                   282 (84) 
Unrelated                                                                               54 (16)
Type of conditioning
Myeloablative                                                                        97 (29) 
RIC                                                                                          239 (71)
GVHD prophylaxis (%)
CsA-Tacro plus MTX                                                            202 (60)
CsA-Tacro plus MMF                                                            37 (11)
T-cell depletion                                                                    91 (27)
Others                                                                                       6 (2)
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Definitions
According to the NIH scoring system, mild cGVHD was diag-
nosed when only one or 2 organs or sites (except the lung) were
involved, with no clinically significant functional impairment
(maximum score 1 in all affected organs or sites). Moderate
cGVHD involved at least one organ or site with clinically signifi-
cant impairment but no major disability (maximum score 2 in any
affected organ or site), or 3 or more organs or sites with no clini-
cally significant functional impairment (maximum score 1 in all
affected organs or sites). A lung score of 1 was also considered
moderate cGVHD. Severe cGVHD was indicated by a major dis-
ability caused by cGVHD (score 3 in any organ or site). A lung
score of 2 or over was also considered ‘severe cGVHD’.4
Patients who were receiving prednisone, or who were still on
a therapeutic dose of cyclosporine due to prior aGVHD that had
evolved into cGVHD without the resolution of symptoms, were
considered as having ‘progressive cGVHD’. Patients who were
on cyclosporine taper with a resolution of symptoms, or who
were free from immunosupression at the time of diagnosis, were
categorized ‘quiescent’, while those without a prior history of
aGVHD were diagnosed with ‘de novo cGVHD’.  Otherwise,
acute and limited versus extensive chronic GVHD were graded
by established criteria.2 Assignment of the patients to the differ-
ent categories for the different classifications was established
according to the organ involvement observed within the first
month of cGVHD diagnosis.
Statistical analysis
Mean and median values, as well as their 95% confidence inter-
vals (CI) and ranges, were calculated for each continuous variable.
The χ2 or Fisher’s exact test was used to establish differences in the
distribution of discontinuous variables, whereas Student's t-test or
Mann-Whitney’s U test was applied to compare continuous vari-
ables. All reported P values are two-sided. P=0.05 was considered
significant. Overall survival was calculated using the Kaplan-Meier
estimate. The log rank test was used for univariate comparisons.
Patients who survived more than 100 days were evaluable for
cGVHD. The incidences of cGVHD and its different subtypes
were calculated from the time of transplantation using cumulative
incidence estimates. Non-relapse mortality (NRM) was defined as
“death due to causes unrelated to the underlying disease” and
relapsing patients were censored at the time of relapse. GVHD
related mortality (cGVHD-RM) was calculated from the time to
cGVHD onset until cGVHD related death, defined as “death due
to causes directly related to GVHD according to primary physician
criteria”. More specifically, among patients diagnosed with
cGVHD, those deaths attributed to complications or failure in
cGVHD-target organs, as well as deaths related to immunosupres-
sion such as infectious complications, in patients requiring treat-
ment for cGVHD were considered as cGVHD related mortalities.
Progression of the underlying malignancy and non-relapse mor-
tality (NRM) without prior cGVHD were competing events for
cGVHD. The starting point (Day 0) for the landmark analysis of
the incidence of cGVHD-RM and NRM was the time of onset of
cGVHD, and the competing events were disease progression and
death not related to cGVHD. Patients who were still alive and pro-
gression-free at the time of analysis were censored at the last fol-
low up or at five years post transplant. Univariate analyses of the
variables that influenced cGVHD-RM and NRM were performed
using proportional hazards models for competing risks (Gray’s
test). The variables that showed at least a trend in univariate
analysis (P<0.1) were used in a multivariate Cox’s proportional
hazards regression analysis, checking for the assumption of pro-
portional hazards over time for each tested variable.
To analyze the incidences and probabilities of later outcomes,
and determine their risk factors in patients who developed
cGVHD, we performed a landmark analysis including only
patients who developed cGVHD. For the analysis of later out-
comes, the starting point for follow up was the day of onset of
cGVHD and not the day of transplant. The methods used for gen-
erating landmark cumulative incidence estimates, survival proba-
bilities, and univariate and multivariate landmark analyses were
identical to those previously described, but of course using the
cGVHD landmark database.
Overall survival (OS) was calculated from transplant until death
from any cause, and surviving patients were censored at the last
follow up. In addition, overall survival from cGVHD onset (OS-
cGVHD) was also calculated from the time of cGVHD diagnosis
until death from any cause. 
All factors that significantly or marginally (P<0.1) influenced the
incidence or outcome of cGVHD in the univariate analysis were
included in a multivariate analysis using a forward step Cox’s
regression model. The statistical analyses were performed using
SPSS version 18.0 (SPSS, Chicago, IL, USA), with the exception of
the cumulative incidence plots which were carried out with NCSS
2004 (Number Cruncher Statistical System, Kaysville, UT, USA)
and the univariate Gray’s test which was carried out using the
Cmprsk package R software (The R Foundation, Vienna, Austria).
Results
Incidence and characteristics of graft-versus-host
disease
First of all, we confirmed that results were similar
among the 3 centers in terms of survival (53%, 52% and
49% at five years, respectively) and NRM (26%, 21% and
30% at five years, respectively). The cumulative incidence
of cGVHD was 48%. Respective values were 26% and
22% for limited and extensive cGVHD, and 14%, 22%
and 17% for mild, moderate and severe cGVHD, respec-
tively. Fourteen percent of patients developed overlap syn-
drome while 13% developed delayed aGVHD. Out of 54
cases of delayed aGVHD, 12 achieved complete remission
after first-line treatment, one progressed and died while
the remaining patients either progressed to cGVHD or had
recurrent delayed aGVHD. 
Cumulative incidences of de novo, quiescent and pro-
gressive cGVHD were 18%, 22% and 8%, respectively. As
far as organ involvement at time of onset is concerned
(Table 2), the most commonly involved organ was oral
mucosa in 65% of patients followed by liver in 56% and
skin in 55% of patients. At the time of cGVHD diagnosis,
36% had a performance score of 0 according to the ECOG
scale and 44% had ECOG 1. Finally, 51% of patients had
involvement of 3 or more organs. 
As far as the characteristics of cGVHD among patients
with classic versus overlap cGVHD is concerned (Table 3),
a significantly higher percentage of patients with overlap
syndrome had a progressive type of onset. In fact, a high
correlation was found between overlap syndrome and
progressive onset (r=0.44, P<0.001). Finally, considering
NIH criteria, a higher number of patients displayed fea-
tures of severe cGVHD among those with overlap syn-
drome compared to those with classic cGVHD.
Prognostic factors for cGVHD-related mortality
Causes of NRM included cGVHD-RM in 21 patients,
fungal infection in 10, viral in 3, respiratory failure in 3,
Prognostic factors in cGVHD
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brain hemorrhage in 2, TTP in one and heart failure in one.
As previously specified, in addition to deaths due to caus-
es directly attributed to complications or failure in cGVHD
target organs, deaths related to immunosupression such as
infectious complications were also considered cGVHD
related mortalities. Variables that significantly influenced
cGVHD-RM are summarized in Table 4. Type of onset,
limited versus extensive cGVHD, as well as NIH score sys-
tem significantly influenced cGVHD-RM. Among vari-
ables included in the NIH score, skin, gut, liver and lung
involvement had the highest impact on mortality together
with performance status. As far as the number of organs
involved is concerned, both a cut-off value of 3 and 4 sig-
nificantly affected the outcome, but the cut-off value of 1-
3 versus 4 or more organs involved had a better predictive
value. Thus, cGVHD-RM was 8% versus 18% for patients
with 1-2 versus 3 or more organs involved (P=0.04) while
these figures were 9% versus 24% for patients with 1-3
versus 4 or more organs involved (P=0.01). Also, platelet
count at the time of cGVHD diagnosis significantly influ-
enced cGVHD-RM for a cut-off value of 100¥109/L.
Finally, patients with overlap syndrome had a significantly
higher mortality compared to those without (23% vs. 8%
cGVHD-RM for patients with and without overlap syn-
drome, respectively; P=0.01). In multivariate analysis, the
development of severe cGVHD according to NIH signifi-
cantly influenced outcome (HR=4.4 (95% CI: 1.3-14.6),
P=0.01). When the variables included in the NIH score
system were entered in the multivariate analysis, perform-
ance status at the time of cGVHD diagnosis [HR=7.9 (3.4-
19), P<0.001] and platelet count [HR=5.1 (1.9-14), P=0.01],
together with severe gut involvement [HR=6.2 (1.8-22),
P=0.01] significantly influenced mortality (Figure 1). Based
on these findings, a new variable was developed with a
score of 0 or 1 for platelets over or below 100¥109/L plus
score 0, 1 or 2 for ECOG 0, 1 or 2 or over. A score of 3 was
given for severe gut involvement irrespective of platelets
and ECOG. This variable allowed different subgroups of
patients to be differentiated in terms of cGVHD related
mortality (Figure 2). Furthermore, when this variable was
included in multivariate analysis it had a higher impact on
outcome (score 2: HR=6.9 (95% CI: 2-24), P=0.002; score
3: HR=26.3 (95% CI 7.4-93) P<0.001 for score 3. In fact,
the same patients with the poorest outcome (score 3)
could be identified by just combining ECOG plus
platelets.
Prognostic factors for OS-cGVHD
The cut-off value of 1-2 versus 3 or more organs involved
did not significantly affect survival while the cut-off value
of 4 retained a significant influence in univariate analysis
(Figure 3). Concerning OS-cGVHD (Table 5), the same
variables affecting cGVHD-RM significantly affected the
outcome (Figure 4). In addition, delayed acute GVHD did
not influence survival while patients with overlap syn-
drome displayed a poorer survival as compared to those
with classic cGVHD (Figure 3). In multivariate analysis,
again NIH classification significantly affected survival
(HR=2.48 (95% CI: 1.38-4.45), P=0.002) for those patients
J.a. Pérez-simón et al.
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Table 2. Chronic GVHD organ involvement.
Characteristics                                                         N=336 (%)
Performance status score
ECOG 0                                                                                    71 (36)
ECOG 1                                                                                    85 (44)
ECOG ≥ 2                                                                                40 (20)
Oral mucosa
No                                                                                            104 (35)
Mild                                                                                         100 (33)
Moderate                                                                                92 (31)
Severe                                                                                       3 (1)
Liver
No                                                                                            133 (44)
Mild                                                                                          66 (22)
Moderate                                                                                65 (22)
Severe                                                                                     35 (12)
Skin
No                                                                                            140 (45)
Mild                                                                                          69 (22)
Moderate                                                                                50 (16)
Severe                                                                                     51 (17)
Ocular involvement
No                                                                                          214 (71.5)
Mild                                                                                          39 (13)
Moderate                                                                                44 (15)
Severe                                                                                      2 (0.5)
Gastrointestinal tract involvement
No                                                                                            220 (74)
Mild                                                                                          40 (13)
Moderate                                                                                35 (12)
Severe                                                                                       4 (1)
Lung
No                                                                                            244 (82)
Mild                                                                                           26 (9)
Moderate                                                                                 21 (7)
Severe                                                                                       7 (2)
Musculoskeletal involvement
No                                                                                            288 (96)
Mild                                                                                            3 (1)
Moderate                                                                                  8 (3)
Severe
N. of organs involved
1 or 2                                                                                       145 (49)
3 or 4                                                                                       122 (41)
5 or more                                                                                30 (10)
Table 3. Characteristics of cGVHD among patients with classic versus
overlap syndrome.
Characteristics Classic Overlap P
cGVHD syndrome
N=336 N=227 N=61
Type of onset (%) 0.001
De novo 46.5 14
Quiescent 46 39
Progressive 7.5* 46
N. of organs involved at onset (%) 0.19
1 or 2 49 55
3 or more 5 45
Limited / extensive cGVHD (%) 0.087
Limited 58 57
Extensive 42 43
NIH score (%) 0.11
Mild 33 36
Moderate 36 28
Severe 31 36
Platelet count (%) 0.2
Mean x 109/L (SD) 79 (112) 104 (85)
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with features of mild or moderate versus severe cGVHD.
In order to analyze which variables had an impact on sur-
vival within those included in the NIH score, we included
the different organs involved in multivariate analysis.
According to this, ECOG (ECOG 1: HR=2.08 (1.11-3.87),
P<0.001; ECOG 2 or more: HR=4.1 (2.14-7.83), P=0.005)
and a platelet count less than 100¥109/L (HR=2.75 (1.71-
4.42), P<0.001) at the time of cGVHD diagnosis, together
with gut involvement (HR=24.06 (4.21-137.4), P<0.001)
significantly affected outcome. Variables with a closer cor-
relation to performance status were skin (r=0.16, P=0.012),
gut (r=0.25, P<0.001) and lung involvement (r=0.29,
P<0.001). 
Finally, we combined ECOG, platelets and gastrointesti-
nal involvariable allowed 4 subgroups of patients to be
clearly identified in terms of outcome (Figure 5); overall
survival was 84% for patients with a combined score of 0
(n=74), 64% for patients with a combined score of 1
(n=93), 43% for patients with a combined score of 2
(n=58) and 0% for patients with a combined score of 3 or
more (n=17). Furthermore, in multivariable involvement
using the previously mentioned score system and again
the new variable analysis, the variable obtained had the
highest impact on survival (score 0: HR=15.96 (95% CI:
6.85-37.17), P<0.001; score 1: HR=5.47 (95% CI: 2.6-11.5),
P<0.001; score 2: HR=2.8 (95% CI: 1.32-5.93), P=0.007). 
As for transplant related mortality, the combination of
ECOG plus platelets also identified the same subgroup of
patients with the worst outcome (score 3). Furthermore,
the combined variable ECOG plus platelets also identified
different subgroups of patients in terms of survival within
the different NIH categories. Therefore, for patients with
mild cGVHD, the combined variable identified patients
with 90%, 61%, 57% and 25% OS (P<0.001); the corre-
sponding values for patients with moderate cGVHD were
93%, 65%, 44% and 0% OS (P=0.001), and the respective
values for severe cGVHD were 66%, 58%, 38% and 0%
OS (P<0.001), respectively.
Discussion
Chronic GVHD (cGVHD) is the major cause of morbid-
ity and mortality in long-term survivors after allogeneic
stem cell transplantation (allo HSCT).  However, cGVHD
is also correlated with a strong graft-versus-malignancy
effect, as previously reported in different hematologic
malignancies.7-9 This complicated relationship between
increased risk for non-relapse mortality and decreased risk
of relapse highlights the importance of defining the group
Table 4. Univariate and multivariate analysis for cGVHD related mortality.
Characteristics cGVHD related P HR (95% CI) P
mortality* univariate multivariate
N=336
Type of onset (%)a <0.001
De novo 4
Quiescent 15
Progressive 29
Overlap syndrome 0.01
No 8
Yes 23
Limited / extensive cGVHD (%) <0.001
Limited 4
Extensive 22
NIH score (%)b <0.001 0.01
Mild 4
Moderate 9
Severe 28 4.4 (1.3-14.6)
Organ involvement (%)
Skin 0/1/2/3 5/16/17/27 0.01
Gut 0/1/2/3c 7/11/39/75 0.001 6.2 (1.8-22) 0.01
Liver 0/1/2/3 9/10/19/21 0.007
Lung 0/1/2/3 10/15/27/30 0.04
Performance status 4/12/38 < 0.001 7.9 (3.4-19) < 0.001
0 / 1 / ≥ 2d
N. of organs involved at onset (%) 0.01
1 to 3 9
4 or more 24
Platelet count (x109/L)
< 100 35 0.001 5.1 (1.9-14) 0.01
≥ 100 10
*Landmark analysis from cGVHD onset to death. asignificant differences for the comparison
between de novo or quiescent versus progressive type of onset; bsignificant differences for the
comparison between mild or moderate versus severe NIH scale; csignificant differences for the
comparison between 0 and 1 versus 2 versus 3 in univariate analysis and HR shown for 0, 1 or
2 versus 3 in multivariate analysis; dsignificant differences for the comparison of 0 versus 1 versus
2 and HR shown for 0 or 1 versus 2 in multivariate analysis. 
Table 5. Univariate and multivariate analysis for OS-cGVHD.
Characteristics Overall survival P HR (95% CI) P
5 years after univariate multivariate
N=336 cGVHD onset
Type of onset (%)a 0.025
De novo 66
Quiescent 57
Progressive 50
Overlap syndrome 0.02
No 68
Yes 52
Limited / extensive 0.008
cGVHD (%)
Limited 70
Extensive 57
NIH score (%)b 0.001
Mild 68
Moderate 66 2.48 (1.38-4.45) 0.002
Severe 48
Organ involvement (%)
Skin 0/1/2/3 74/60/52/48 0.003
Gut 0/1/2/3c 67/65/33/0 <0.001 29.48 (4.9-175) <0.001
Liver 0/1/2/3 67/64/64/19 0.051
Lung 0/1/2/3 64/59/55/19 0.026
Performance 79/61/33 <0.001 4.1 (2.14-7.83) P=0.005
status 0 / 1 / ≥ 2d
N. of organs involved at onset (%) 0.035
1 to 3 65
4 or more 54
Platelet count (¥109/L) <0.001
< 100 36
≥ 100 69 2.75 (1.71-4.42) <0.001
aSignificant differences for the comparison between de novo versus quiescent or progressive
type of onset; bsignificant differences for the comparison between mild or moderate versus
severe NIH scale; csignificant differences for the comparison between 0 and 1 versus 2 versus
3 in univariate analysis and HR shown for 0, 1 or 2 versus 3 in multivariate analysis; dsignificant
differences for the comparison of 0 versus 1 versus 2 and HR shown for 0 or 1 versus 2 in mul-
tivariate analysis.
Prognostic factors in cGVHD
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of patients who may benefit from systemic immune-sup-
pression versus those who may just require topical or local
treatment.
The first classification of cGVHD into limited or exten-
sive forms was based on 20 patients and was aimed at sep-
arating patients who needed systemic rather than local or
topical therapy.2 Unfortunately, most patients are finally
categorized as having extensive cGVHD, especially
among those receiving peripheral blood progenitor cells.10
In 2005, the NIH published consensus criteria for diagno-
sis of cGVHD that establish the diagnosis of acute or
chronic GVHD on the basis of the clinical manifestations
and not the time of onset.4 Furthermore, the NIH estab-
lished a scoring system in an attempt to identify those
patients who may require systemic treatment or those
who may benefit from topical treatment only. Although
this classification has been evaluated in several stud-
ies,3,5,6,11 its prognostic value has not been evaluated in a
multicenter study in a large series of patients.
Furthermore, few studies have evaluated the prognostic
value of the new entities, delayed acute and overlap syn-
drome, proposed by the NIH with contradictory
results.3,6,12
Therefore, we aimed to evaluate the prognostic value of
the published NIH consensus criteria on cGVHD, focusing
on developing a simple scoring system, and evaluation of
the prognostic value of the new entities proposed by the
NIH.
The incidence of cGVHD in this study was 48% which
is in line with previous reports, although the reported inci-
dence varies between 6% and 80%.1,10,13,14 The reasons for
this disparity are multi-factorial and include diagnosis,
type of donor,15 conditioning regimen, GVHD prophylax-
is,7 stem cell source,14 graft manipulation,16 use of donor
leukocyte infusion (DLI),17 etc. In addition, the lack of
standardized diagnostic criteria is also likely to be an
important reason for this heterogeneity in the incidence of
cGVHD.
Our retrospective study included patients from 3 differ-
J.a. Pérez-simón et al.
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Figure 1. Landmark plots
illustrating the impact of (A)
the NIH severity score; (B)
the ECOG ≥ 2, 1 and 0 per-
formance status; (C) the
platelet count <100 and
>100x109/L; and (D) the
severity of gut involvement
on the incidence of cGVHD-
related mortality.
Figure 2. Landmark plot illustrating the impact of the new compos-
ite variable on the incidence of cGVHD-related mortality. The com-
posite variable has a value of 0 to 3 based on the sum of platelet
count < 100x109/L (1 point) and the ECOG performance status (0, 1
or 2 points for ECOG of 0, 1 o ≥2). In addition, patients with severe gut
involvement were assigned 3 points irrespective of platelets and ECOG.
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ent European centers. Medical records of 336 patients who
developed cGVHD were evaluated and organ involvement
was categorized according to NIH criteria if the medical
records contained documentation showing unequivocal
manifestations. Transplant related mortality and overall
survival was similar for all 3 centers indicating a homoge-
neous study population.
As far as the new sub-categories proposed by the NIH
are concerned, we can confirm that delayed acute cGVHD
has no adverse effect on outcome. This is in agreement
with conclusions of Vigorito et al.5 In addition to these
data, in the current study we were able to evaluate the
outcome of delayed aGVHD and observed that a signifi-
cant proportion of patients subsequently developed recur-
rent delayed acute or chronic GVHD. These data would
suggest that, in terms of immune suppressive treatment,
these patients should be initially managed as aGVHD but
treatment should be maintained for a longer period of
time. 
Contrary to delayed aGVHD, overlap syndrome is an
Prognostic factors in cGVHD
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Figure 3. (A) Overall survival from cGVHD diagnosis for patients with 1-3 versus ≥ 4 organs involved (B) for patients with classic cGVHD
versus overlap syndrome and (C) for patients with delayed aGVHD versus classic cGVHD.
Figure 4. (A) Overall survival from cGVHD diagnosis for patients with mild, moderate or severe cGVHD (B) for patients with ECOG 0, 1 and
≥ 2 (C) for patients with platelets <100 and >100x109/L and (D) for patients with gut score 3, 2, 1 and 0.
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adverse prognostic factor. This finding has been reported
previously.11 It is worth mentioning that a high percentage
of patients categorized as having overlap syndrome had a
progressive type of onset so that both variables were high-
ly correlated. In this retrospective analysis, we carefully
tried to differentiate between patients who had signs or
symptoms of aGVHD that were resolving at the moment
in which the signs or symptoms of cGVHD appeared, i.e.
classic cGVHD with progressive type of onset from those
who developed both active signs or symptoms of acute
and chronic GVD, i.e. true overlap syndrome.
Nevertheless, these data must be confirmed in prospective
studies. 
We confirmed that NIH criteria are the most important
variables in predicting outcome in multivariate analysis.
Nevertheless, only severe forms can be clearly differentiat-
ed in terms of outcome while mild and moderate disease
had rather similar outcomes. Among those variables
included in the NIH, performance status according to
ECOG score and platelet counts at the time of cGVHD
had the highest impact on outcome, both in terms of
cGVHD-RM and survival. In addition, gastrointestinal
involvement significantly influenced outcome in multi-
variate analysis while skin, liver and lung involvement also
affected outcome in univariate analysis. By contrast
mouth, eyes and musculoskeletal involvement did not
influence outcome. In fact, skin, liver and lung involve-
ment had a high correlation with ECOG and, accordingly,
are responsible for the performance score of the patients at
the time of cGVHD. 
According to these data we created a new score system
which, in fact, was much more powerful than NIH in
predicting outcome and far easier to perform. Thus,
greater ECOG score in combination with a low platelet
count together with severe gastrointestinal involvement
are strong prognostic factors for cGVHD-RM and OS.
Interestingly, the simple combination of ECOG plus
platelet count allowed us to discriminate the same sub-
groups of patients suggesting that this combination has
prognostic impact and could be applied irrespective of
the organs involved. Larger studies with a higher number
of patients with severe involvement of skin, liver or lung
are required to confirm these data and also to confirm the
prognostic value of this score within the different NIH
subgroups. Interestingly, Lee S et al.18 reported that
Karnofsky performance score, diarrhea, weight loss, and
cutaneous and oral involvement are independent prog-
nostic factors among patients with cGVHD. While we
did not find cutaneous or oral involvement to be inde-
pendent prognostic factors, the prognostic value of per-
formance score and gastrointestinal involvement (mani-
fested as diarrhea and/or weight loss) are confirmed in
the current study. By contrast, we also found platelet
count to be an independent prognostic factor, similar to
the study by Akpek et al.19 which described extensive skin
involvement, progressive type of onset and thrombocy-
topenia as independent prognostic factors. While we also
found these variables to have a prognostic value in uni-
variate analysis, only thrombocytopenia was confirmed
in multivariate analysis. In a recent large retrospective
study, Arora et al.20 developed a new score system among
patients with cGVHD which, similar to the current study,
also identifies platelet count and performance status as
the most important prognostic factors at the time of
cGVHD diagnosis. In contrast to the current manuscript,
their study is based on registry data so that no specific
analysis can be provided regarding either the impact of
organ involvement or the NIH classification on outcome.
By contrast, Arai et al.21 have recently reported a prospec-
tive study which confirms the impact of the NIH classifi-
cation on outcome. Interestingly, the percentage of
patients diagnosed with mild cGVHD is much lower than
the current study although, as discussed by the authors,
the requirement of systemic treatment in order to enroll
the patients in the cohort could be a reason why the inci-
dence of cGVHD was underestimated. It is worth men-
tioning the similarities in terms of cGVHD related mor-
tality in the different NIH subgroups in both studies. By
contrast, the survival reported by Arai et al. is better for
the different NIH subgroups than the current study.
Median follow up in their series is 18 months while the
current series of patients were transplanted between
2000 and 2006; this could at least in part justify the dif-
ference. 
Interestingly, NIH proposed a cut off of involvement of
3 organs in order to distinguish mild from moderate
cGVHD4 so that, according to this classification, systemic
immune suppression is recommended for patients with
involvement of 3 organs. Since ours is a retrospective
study, we cannot draw any conclusions about the best
treatment for patients with involvement of 3 organs but,
according to our data, these patients had a similar survival
to those with 1-2 organs involved and a significantly bet-
ter survival than those with 4 or more organs involved.
Thus, further studies will be required to confirm the best
cut off for systemic treatment.
In conclusion, we have identified a simple prognostic
tool that does not take too long to identify different sub-
groups of patients in terms of cGVHD-RM and survival.
Regarding the new entities proposed by NIH, delayed
acute GVHD did not influence outcome while overlap
syndrome did. Finally, involvement of 4 or more organs
with moderate scores according to NIH criteria is
required before systemic immune suppression should be
started.
J.a. Pérez-simón et al.
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Figure 5. Overall survival from cGVHD diagnosis depending on the
variable which resulted from combining ECOG, platelets and gas-
trointestinal involvement. The four graphs show overall survival for
patients with a score of 0 (84%), 1 (64%), 2 (43%) and ≥3 (0%).
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